Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades

Table 3

Frequency of antibody response toward KRR1 and ZRF1 antigens in the sera of patients of different histological types of breast tumors in view of .

Antigen	The number of positive sera, n (%)
	HD over 45 ()	HD under 45 ()	BC over 45 ()	MBC over 45 ()	IDC over 45 ()	ILC over 45 ()	FA under 45 ()
ZRF1	1 (4,76)	1 (2.86)	28 (25,00)	1 (14,29)	22 (26,83)	5 (21,74)	2 (10,00)
Mean ± SD	0,1513 ± 0,057	0,1446 ± 0,049	0,2242 ± 0,132	0,20534 ± 0,061	0,2383 ± 0,144	0,18 ± 0,084	0,1706 ± 0,094
KRR1	0 (0)	2 (5,71)	23 (20,54)	1 (14,29)	21 (25,61)	1 (7,14)	0 (0)
Mean ± SD	0,2288 ± 0,080	0,2403 ± 0,060	0,3246 + 0,080	0,2843 ± 0,072	0,3430 ± 0,077	0,2712 ± 0,068	0,1884 ± 0,054

Notes: statistical analysis of frequency of antibody response was calculated between BC patients and healthy individuals cohorts over 45 years old and between FA and healthy individuals cohorts under 45 years old; threshold: the mean plus 2 SD in the group of healthy donors; Statistically significant difference compared to healthy donors’ sera (). HD: healthy donors; BC: breast cancer (IDC + ILC + MBC); MBC: medullary breast carcinoma; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; FA: fibroadenoma.